Agents That Block Plasma IgG Recycling: The Next Big Thing for IgG Antibody-Mediated Diseases?
New FcRn inhibitors may be a viable therapeutic option for certain patients currently treated withIG and plasma exchange.
IVIG Manufacturing Process for Bivigam Approved by FDA
ADMA Biologics has received approval from FDA for its prior approval supplement for Bivigam, allowing the company to use its optimized IVIG manufacturing process and market Bivigam to PI patients in the U.S.
IVIG Therapy Reduces In-Hospital Mortality and Ventricular Function Loss in Patients with Acute Myocarditis: Meta-Analysis
Investigators at the Huazhong University of Science and Technology conducted a meta-analysis of published clinical trials that evaluated IVIG therapy in acute myocarditis.
The Many Faces of Parvovirus B19: IVIG to the Rescue?
This common virus manifests in a host of systemic illnesses that are mostly curable with human intravenous immune globulin therapy.
Neonatal Fc Receptor Antagonist Efgartigimod Sustainably Reduces Circulating IgG Level in Humans
Investigators from the Belgian biotechnology company argenx and U.S. collaborators conducted a PhaseI clinical study to assess a novel modified antibody Fc fragment (efgartigimod) that reduces the circulating IgG level by blocking neonatal Fc receptor-mediated IgG recycling.
Improved Social and Behavioral Scores Following IVIG Therapy Suggest a Neuroimmune Etiology in Some Children with Autism
In the largest case series of children with autism spectrum disorder (ASD) treated with IVIG, researchers identified brain-targeted autoantibodies in children with ASD.
Subcutaneous Immune Globulin Maintenance Therapy for CIDP: An Idea Whose Time Has Come
A potential solution for CIDP patients with these IVIG-related issues is self-administered subcutaneous immune globulin.
Cognitive, Behavioral and Neuroinflammatory Parameters Improve in Autistic Children Treated with Intravenous Immune Globulin
A pilot study conducted by U.S. investigators observed improvements in cognitive and behavioral function in 14 children with autism spectrum disorder and evidence of immune dysfunction who were administered high-dose intravenous immune globulin (IVIG) treatment over a period of 30 weeks.
Grifols’ Higher-Potency Rabies Immune Globulin Is Now Available
Grifols’ higher-potency rabies immune globulin (RIG), HyperRAB S/D, was made available to healthcare providers
CSL Behring Will Discontinue Carimune NF in Third Quarter 2018
Discontinuation of the product is due to the preference among healthcare professionals and patients for newer, more advanced immune globulin options.
